Original ArticleLong-Term Efficacy of Initial Microvascular Decompression Versus Subsequent Microvascular Decompression for Idiopathic Hemifacial Spasm
Introduction
Hemifacial spasm (HFS) is a disorder characterized by intermittent, involuntary facial muscle contractions, leading to impaired quality of life. Compression of the facial nerve by offend vessel is the most common identifiable reason of HFS.1, 2, 3 With a high curative rate from 50% to 98%, microvascular decompression (MVD) has been regarded as the gold standard treatment for HFS.4, 5 However, some patients choose to undergo less-invasive procedures before MVD, such as botulinum neurotoxin type A (BtNtA).6, 7 BtNtA exerts its effect by preventing the liberation of acetylcholine into the synaptic cleft, leading first to functional and then to physical muscle denervation.8 However, the long-term efficacy and safety of subsequent MVD have not been established. In the present study, we retrospectively investigated the characteristics, immediate and long-term outcomes, complications, and vascular decompression in patients experiencing an MVD performed as their first surgical intervention and patients experiencing an MVD performed as a subsequent surgical intervention.
Section snippets
Patient Population
This study and the technique of MVD were approved by Xinhua Hospital Ethics Institutional Committee. Each patient involved in this study signed an informed consent form. All methods were carried out in accordance with approved institutional guidelines and regulations. From January 2008 to October 2010, our department treated 1029 patients with primary HFS via MVD. We identified and excluded 12 patients with bilateral HFS, and 41 patients were lost to follow-up, leaving 976 patients for
Demographics
Table 1 presents the patient demographics. The mean age at intervention was 68.24 years for patients in group A and 67.43 years in group B (P = 0.75). The mean HFS symptom duration was 5.25 years for patients in group A and 6.43 years for patients in group B (P = 0.47). There were not significant differences in mean age at MVD and HFS symptom duration between the 2 groups. In addition, the number of female patients and side of HFS were well matched between the 2 groups. Table 2 presents the
Discussion
MVD has been reported to be the only surgical therapy that directly treats the proposed etiology of HFS. Many studies10, 11 have been published regarding the high efficacy of MVD for patients with HFS, with cure rates ranging anywhere from 50% to 98%, and excellent long-term results 10 years after MVD in 84% of patients. However, it is an invasive procedure and not without certain risks. Some patients are inclined to receive multiple noninvasive local injections of BtNtA or radiosurgery before
Conclusions
The low complication rate and excellent outcome suggest that MVD is an effective and safe treatment for patients with HFS. In addition, patients undergoing MVD for HFS as the primary treatment experience better long-term efficacy than patients who were first treated with BtNtA.
References (20)
- et al.
Results of atypical hemifacial spasm with microvascular decompression: 14 cases report and literature review
World Neurosurg
(2017) Viral titers and delayed facial palsy after acoustic neuroma surgery
Otolaryngol Head Neck Surg
(2002)- et al.
Hearing outcomes after loss of brainstem auditory evoked potentials during microvascular decompression
J Clin Neurosci
(2015) - et al.
Postoperative complications of microvascular decompression for hemifacial spasm: lessons from experience of 2040 cases
Neurosurg Rev
(2016) - et al.
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms
Mov Disord
(2011) - et al.
Long-term outcome of microvascular decompression for hemifacial spasm
Br J Neurosurg
(2017) - et al.
Microvascular decompression for hemifacial spasm associated with bilateral vertebral artery compression
World Neurosurg
(2015) - et al.
The efficacy and safety of microvascular decompression for hemifacial spasm in elderly patients
J Korean Neurosurg Soc
(2010) - et al.
Safety and effectiveness of microvascular decompression for the treatment of hemifacial spasm in the elderly
Eur Neurol
(2013) - et al.
Treatment of hemifacial spasm with botulinum toxin type A: effective, long lasting and well tolerated
Arq Neuropsiquiatr
(2017)
Cited by (5)
Microvascular Decompression
2022, Intraoperative Monitoring: Neurophysiology and Surgical ApproachesEfficacy and Complications of Microsurgical Neurovascular Decompression in 55 Patients With Hemifacial Spasm
2021, Otolaryngology - Head and Neck Surgery (United States)Two-dimensional structure analysis of hemifacial spasms and surgical outcomes of microvascular decompression
2021, Neurological ResearchMicrovascular decompression: is routine postoperative CT imaging necessary?
2020, Acta Neurochirurgica
Conflict of interest statement: This study was supported by the Shanghai Xinhua Hospital Foundation (grants 15LC21 and 15YJ05), Shanghai Jiao Tong University Medical and Engineering Cross Fund (grants YG2016ZD11 and YG2016QN68), and the Natural Science Foundation of China (grants 81401033 and 81671205).
Hua Zhao, Guang-feng Li, Xin Zhang, Yin-da Tang, Ping Zhou, and Jin Zhu are co–first authors.